David Ricks, Eli Lilly CEO (Jeenah Moon/Bloomberg via Getty Images)
July 2, 2024 02:02 PM EDTUpdated 03:20 PM
Pharma
FDA+

Up­dat­ed: Eli Lil­ly wins long-await­ed ap­proval for Alzheimer’s drug

Ryan Cross

Senior Science Correspondent

Af­ter decades of try­ing to de­vel­op a treat­ment for Alzheimer’s dis­ease, Eli Lil­ly has fi­nal­ly won FDA ap­proval for its drug do­nanemab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In biotech's un­even re­cov­ery, 50 star­tups raised megarounds in first half of 2024

Ex­perts want to make it eas­i­er to get RSV vac­cines. Did they make it hard­er in­stead?

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

Flag­ship ap­pears to boost tar­get of eighth fund by up to $500M

Pfiz­er adds ex-State Street CEO to the board; Two Merus ex­ecs head for the ex­it

GSK re­works Cure­Vac deal, pay­ing $429M up­front to grab con­trol of mR­NA flu and Covid vac­cines 

A service from the Financial Times